Therefore, the potential use of PACAP/PAC1 agonists as novel pharmacological agents in the treatment of appetite disorders, obesity and metabolic syndrome is promising and needs further exploration. The gene discussed is ADCYAP1R1; the disease is obesity due to melanocortin 4 receptor deficiency.